Log In
Print
BCIQ
Print
Print this Print this
 

yttrium-90-clivatuzumab tetraxetan (Y-90 hPAM4) (formerly IMMU-107)

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionYttrium-90 radiolabeled humanized mAb against MUC1
Molecular Target Mucin 1 (MUC1) (CD227)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPancreatic cancer
Indication DetailsTreat metastatic pancreatic cancer; Treat pancreatic cancer
Regulatory Designation

U.S. - Fast Track (Treat pancreatic cancer)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today